A Phase II Open-Labeled Study to Evaluate CardioPET as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects With Coronary Artery Disease

Trial Profile

A Phase II Open-Labeled Study to Evaluate CardioPET as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects With Coronary Artery Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Fluorine-18 flurorocyclopropylhexadecanoic acid (Primary)
  • Indications Coronary artery disease
  • Focus Diagnostic use
  • Sponsors FluoroPharma
  • Most Recent Events

    • 26 Sep 2016 Results published in a FluoroPharma media release.
    • 26 Sep 2016 Results presented at the 21st Annual Meeting of the American Society of Nuclear Cardiology, according to a FluoroPharma media release.
    • 25 May 2016 According to FluoroPharma media release, the company announced acceptance of CardioPET data for presentation at 21st Scientific Meeting of the American Society of Nuclear Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top